Rittal Mehta

ORCID: 0000-0002-0807-4763
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pancreatic and Hepatic Oncology Research
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Gallbladder and Bile Duct Disorders
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Congenital Heart Disease Studies
  • Cardiac, Anesthesia and Surgical Outcomes
  • Healthcare Policy and Management
  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Screening and Detection
  • Cardiac Structural Anomalies and Repair
  • Liver Disease Diagnosis and Treatment
  • Neuroendocrine Tumor Research Advances
  • Pancreatitis Pathology and Treatment
  • Enhanced Recovery After Surgery
  • Cardiovascular Issues in Pregnancy
  • Sepsis Diagnosis and Treatment
  • Liver Disease and Transplantation
  • Cardiac Valve Diseases and Treatments
  • Health Systems, Economic Evaluations, Quality of Life
  • Viral-associated cancers and disorders
  • Economic and Financial Impacts of Cancer
  • Childhood Cancer Survivors' Quality of Life
  • Cardiac Arrest and Resuscitation
  • Lung Cancer Research Studies
  • Patient Satisfaction in Healthcare

Children's National
2023-2025

National Hospital
2023-2025

Henry M. Jackson Foundation
2021-2024

George Washington University
2023-2024

University of California, San Francisco
2024

Bodyline Hospitals
2023

Jackson Foundation
2021-2022

The Ohio State University Wexner Medical Center
2008-2021

The Ohio State University
2008-2021

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2019-2021

Abstract Background Although the Barcelona Clinic Liver Cancer (BCLC) staging system has been largely adopted in clinical practice, recent studies have emphasized need for further refinement and subclassification of this system. Methods Patients who underwent hepatectomy with curative intent BCLC-0, -A or -B hepatocellular carcinoma (HCC) between 2000 2017 were identified using a multi-institutional database. The tumour burden score (TBS) was calculated, overall survival (OS) examined...

10.1002/bjs.11464 article EN British journal of surgery 2020-02-14

Objective: The objective of the current study was to define surgical outcomes after resection multinodular hepatocellular carcinoma (HCC) beyond Milan criteria, and develop a prediction tool identify which patients likely benefit most from resection. Background: Liver for HCC, especially remains controversial. Rigorous selection best candidates is essential achieve optimal liver advanced tumors. Methods: Patients who underwent HCC between 2000 2017 were identified an international...

10.1097/sla.0000000000004346 article EN Annals of Surgery 2020-09-10

BackgroundThe association between the prevalence of cirrhosis and types Fontan operations remains unclear.MethodsWe conducted a retrospective chart review 332 patients who underwent procedure at our institution. Four atriopulmonary connection were excluded from analysis. Patients had intracardiac-extracardiac conduit (126) 1989 2021 pooled with those having extracardiac (ECC) (134). The 260 ECC 68 lateral tunnel (LT) constitute core study.ResultsMedian age was 23.7 months (interquartile...

10.1016/j.jtcvs.2024.04.013 article EN cc-by-nc-nd Journal of Thoracic and Cardiovascular Surgery 2024-04-28

The objective of the current study was to define and compare rates textbook outcomes (TO) among patients undergoing colorectal, lung, esophagus, liver, pancreatic surgery for cancer at U.S. News & World Report (USNWR) ranked hospitals.Medicare Inpatient Standard Analytic Files 2013-2015 were utilized examine relationship TO USNWR hospital ratings following esophageal, pancreatic, liver cancer. defined as no postoperative surgical complications, prolonged length stay, readmission within 90...

10.1002/jso.25833 article EN cc-by-nc Journal of Surgical Oncology 2020-03-02

Abstract Background and Objective Financial hardship occurring as a result of cancer treatment has been termed financial toxicity is an established side effect the treatment. We investigated risk among patients undergoing surgery for gastrointestinal cancers. Methods All uninsured privately insured who underwent were identified from National Inpatient Sample. Publicly available government data used estimate income, food expenditure, average maximum out‐of‐pocket expenditure. Risk was defined...

10.1002/jso.25605 article EN Journal of Surgical Oncology 2019-06-24

<h3>Importance</h3> Typically defined as the top 5% of health care users,<i>super-utilizers</i>are responsible for an estimated 40% to 55% all costs. Little is known about which factors may be associated with increased risk long-term postoperative super-utilization. <h3>Objective</h3> To identify clusters patients distinct constellations clinical and comorbid patterns who elevated super-utilization in year following elective surgery. <h3>Design, Setting, Participants</h3> A retrospective...

10.1001/jamasurg.2019.2979 article EN JAMA Surgery 2019-08-15

Abstract Background The aim of the current study was to identify minimum number and optimal range lymph nodes (LNs) be examined among patients with gallbladder cancer (GBC). Methods Between January 1, 2004, December 31, 2015, a diagnosis GBC were identified in National Cancer Database. A machine‐based learning approach used LNs evaluate relative long‐term outcomes. Results Among 6531 GBC, median evaluated 2 (IQR:1‐5); only 21.1% (n = 1376) had 6 or more evaluated. metastatic 0 (IQR: 0‐1). On...

10.1002/jso.25450 article EN Journal of Surgical Oncology 2019-03-12

Few data are available regarding the management and outcomes among patients with sarcomatoid hepatocellular carcinoma (HCC) due to its rarity.Patients diagnosed HCC from 2004 through 2015 were identified in National Cancer Data Base. Overall survival (OS) was calculated versus conventional using a 1:3 propensity score matching based on sex, age, American Joint Committee (AJCC) stage of disease.The final analytic cohort included 104 312 HCC. Patients more often had larger median tumor size...

10.1002/cncr.32396 article EN Cancer 2019-07-12
Coming Soon ...